Chronic or Acute Advanced Heart FailureSOFCARNCT02877446
South Of France Cardiac Assist Registry
An observational study of Chronic or Acute Advanced Heart Failure, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Chronic heart failure is a common disease. It is also a serious disease with a mortality of 50% at 5 years, representing a significant cost in terms of public health expenditure. Read more about this study
- Who is it for?
- Ages 18 to 100 years, women only
- Conditions the study is for
- Chronic or Acute Advanced Heart Failure
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- Jan 2016to 10 Aug 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients who underwent surgical LVAD implantation in one of the 3 participating centers (University Hospital of Montpellier, Toulouse and Bordeaux, France) for a period of 3 years, will be consecutively included whatever type of LVAD (Heartmate 2 or 3®, Jarvik®, Heartware®,…). Patients will be follow-up at 1 and 6 months, and 1 year. Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. Study of phenotypic characteristics will not change therapeutic approach of the medical teams.
Who may be able to join
- All patients undergoing implantation of LVAD support whatever make and type on one of the 3 participating centers (University Hospital of Montpellier, Toulouse and Bordeaux) during the period
- Free, informed and signed consent
- Adults
- Men or women Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. Study of phenotypic characteristics will not change the therapeutic approach of the medical teams.
Who cannot join
- Patient unable to understand the nature and goals of the study and / or communication difficulties with the investigator
- Major protected by law (guardianship, curatorship or under judicial protection)
- Patient deprived of liberty by judicial or administrative decision
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Observatoire Des Assistances Monoventriculaires Gauches du Grand Sud
Chronic heart failure is a common disease. It is also a serious disease with a mortality of 50% at 5 years, representing a significant cost in terms of public health expenditure.
Heart transplantation represents the "gold standard" of care for terminal heart failure patients reached the end of the disease despite optimal medical and surgical management of their disease, with a survival rate of transplant patients by 90% at 1 year and 82% at 3 years.
Read more
Long term LVAD are an innovative technology available for more than a decade, developed in part because of the shortage of cardiac grafts and high mortality among patients waiting for transplants due to an important pending.
This technique is used substantially only for ten to fifteen years in the world. Survival after implantation of latest devices reaches 80% at 1 year.
In France, this technique is intended for patients with terminal heart failure who ended different pharmacological and invasive therapeutic resources available.
Currently, academic centers that offer the possibility of long-term LVAD support are organized unicentric in order to centralize specialized care for these patients.
Indeed, patients candidates for the establishment of a long-term LVAD are rigorously selected to ensure an acceptable survival.
However, practices vary considerably from one center to another in particular regarding:
- Implantation indications,
- Pre-implantation patient assessment,
- Monitoring,
- Implementation of pharmacological treatments, particularly anticoagulants or betablockers.
Read the detailed description
Methods:
It's a prospective multicentric observational study realised on 3 University Hospital in France: Bordeaux, Montpellier and Toulouse.
Population:
All patients undergoing implantation of a long-term LVAD support whatever the brand and type, on one of the 3 participating centers (Montpellier, Toulouse or Bordeaux) during the 3 years period, after approval of informed consent.
Patients were followed up at 1 and 6 months, and 1 year as part of their routine management of their disease.
Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the team responsible for the patient.
Aim:
Main aim is 1 year mortality of LVAD recipients
Secondary aim are:
- Descriptive epidemiology of LVAD implantation: prevalence, etiology, affected populations
- Description of the state of practice: indications, against-indications, preimplantation data, intraoperative data, postoperative data, tracking data
- Rating prognosis of patients under LVAD support
- In-hospital, 30 days, 6 months, and 1 year survival
- Number of transplanted and assisted patients at 1 year
- Evaluation of complications (infections, bleeding, thromboembolism, equipment failures, ...)
- Analyses in subgroups according to age, sex, initial indication (including ischemic heart disease vs nonischemic), assistance used and year of implantation
- Research of prognostic factors for postoperative and chronic right ventricular failure, prognostic factors of cardiovascular and all causes death.
Feasibility:
Based on historical data of the concerned centers (CHU Montpellier, Bordeaux and Toulouse) and recent predictions of french health authority HAS ("Haute Autorité de Santé"), 200 patients are provided in the observatory register, rhythm about 20-30 patients per year per center for a 3-year recruitment period Monitoring will be carried out by the referring physician for each patient at 1 and 6 months, and at 1 year in the usual care of pathology in each center with the possibility to adapt the follow-up date to +/- 1 month.
For patients who have moved and have therefore changed of referral center, an evaluation at one year will be made by mail or phone contact with the physician and / or patient.
Collect and circulation of patients' data:
Data will be collected under the patient's referring physician's responsibility in each center. Data will be entered directly into the electronic database (e-CRF) developed University of Montpellier.
Patient will be identified by the number of the center (1 = Bordeaux, 2 = Montpellier 3 = Toulouse) followed by the first letter of the name and the first initial and the center of the patient number in question (automatic chronological number according to the entry on the e-CRF - data coding is integrated into the e-CRF) Monitoring at 1 month, 6 months and 1 year, will be completed by the middle of referring physicians and entered directly into the electronic database.
There will be no traffic data on paper for these two steps.
In case of lost sight, follow-up at 1 year will be carried out by the centers, by phone or mail from the municipality of birth, the attending physician or cardiologist and patient, which requires knowledge of the date full birth patients to avoid confusion.
For the analysis, data will be anonymized (as shown above).
Members of the scientific committee, persons responsible for logistics and coordination statistics will have access to all of the identified data.
Research data is entered via an electronic case report forms (e-CRF) developed from the Capture System software (CLINSIGHT company), enabling quality control of data in real time. To meet regulatory requirements, this software complies with the FDA's recommendations on Computerized Systems for Managing Clinical Trials and electronic signature and standards (CDISC, ICH, GCP 2001/20 / EC ...). The connection is via a password and a unique identifier specific to each user that will give access only to his patients himself. An audit function is integrated allowing traceability of data as well as changes. The encrypted data will then be transmitted to the responsible center of the data-management via a secure internet connection.
The e-CRF must be composed of all the information required by the protocol.
Information and Consent of participants:
Prior to the completion of this research, the free, writing and informed consent of patients must be collected after information by the investigator during a consultation, and after a sufficient period of reflection.
Participants information for research should be written simply, in language understandable by the patient. After having read the participant and the investigator will have dated and signed the consent form (original archived by the investigator and an original will be given to research participants).
- Conditions
- Chronic or Acute Advanced Heart Failure
- Keywords
- Left ventricular assist device (LVAD), Terminal heart failure, Ventricular assist device (VAD)
- Medical subject headings
- Bronchiolitis Obliterans Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality rate
Mortality rate after one year for patients included in the research
Measured: 1 year
Secondary outcomes (6)
Cardiovascular death rates
Search prognostic factors for postoperative ventricular failure and chronic right, prognostic factors of cardiovascular death and all-cause
Measured: 30 days
Cardiovascular death rates
Search prognostic factors for postoperative ventricular failure and chronic right, prognostic factors of cardiovascular death and all-cause
Measured: 6 months
Cardiovascular death rates
Search prognostic factors for postoperative ventricular failure and chronic right, prognostic factors of cardiovascular death and all-cause
Measured: 1 year
Mortality rate
Measured: 30 days
Mortality rate
Measured: 6 months
vital function
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2016 (estimated)
- Study startJan 2016
- Primary completionApr 2022
- Study completion10 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic or Acute Advanced Heart FailureStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Toulouse, University Hospital, Bordeaux
- Responsible party
- Sponsor
- Investigators
- Francois Roubille, MD PHD, Principal investigator, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02877446
- Sponsor's protocol ID
- 9690
- Acronym
- SOFCAR
- Status last verified
- Apr 2022
- First submitted
- 8 Jul 2016
- Last updated
- 11 Aug 2022
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided: ND
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observatoire Des Assistances Monoventriculaires Gauches du Grand Sud
- ClinicalTrials.gov ID
- NCT02877446
- Acronym / sponsor ID
- SOFCAR / 9690
- Conditions
- Chronic or Acute Advanced Heart Failure
- Keywords
- Left ventricular assist device (LVAD), Terminal heart failure, Ventricular assist device (VAD)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Collaborators
- University Hospital, Toulouse, University Hospital, Bordeaux
- Study start
- Jan 2016 (actual)
- Primary completion
- Apr 2022 (actual)
- Study completion
- 10 Aug 2022 (actual)
- First posted
- 24 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic heart failure is a common disease. It is also a serious disease with a mortality of 50% at 5 years, representing a significant cost in terms of public health expenditure.
Heart transplantation represents the "gold standard" of care for terminal heart failure patients reached the end of the disease despite optimal medical and surgical management of their disease, with a survival rate of transplant patients by 90% at 1 year and 82% at 3 years.
Long term LVAD are an innovative technology available for more than a decade, developed in part because of the shortage of cardiac grafts and high mortality among patients waiting for transplants due to an important pending.
This technique is used substantially only for ten to fifteen years in the world. Survival after implantation of latest devices reaches 80% at 1 year.
In France, this technique is intended for patients with terminal heart failure who ended different pharmacological and invasive therapeutic resources available.
Currently, academic centers that offer the possibility of long-term LVAD support are organized unicentric in order to centralize specialized care for these patients.
Indeed, patients candidates for the establishment of a long-term LVAD are rigorously selected to ensure an acceptable survival.
However, practices vary considerably from one center to another in particular regarding:
- Implantation indications,
- Pre-implantation patient assessment,
- Monitoring,
- Implementation of pharmacological treatments, particularly anticoagulants or betablockers.
Detailed description
Methods:
It's a prospective multicentric observational study realised on 3 University Hospital in France: Bordeaux, Montpellier and Toulouse.
Population:
All patients undergoing implantation of a long-term LVAD support whatever the brand and type, on one of the 3 participating centers (Montpellier, Toulouse or Bordeaux) during the 3 years period, after approval of informed consent.
Patients were followed up at 1 and 6 months, and 1 year as part of their routine management of their disease.
Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the team responsible for the patient.
Aim:
Main aim is 1 year mortality of LVAD recipients
Secondary aim are:
- Descriptive epidemiology of LVAD implantation: prevalence, etiology, affected populations
- Description of the state of practice: indications, against-indications, preimplantation data, intraoperative data, postoperative data, tracking data
- Rating prognosis of patients under LVAD support
- In-hospital, 30 days, 6 months, and 1 year survival
- Number of transplanted and assisted patients at 1 year
- Evaluation of complications (infections, bleeding, thromboembolism, equipment failures, ...)
- Analyses in subgroups according to age, sex, initial indication (including ischemic heart disease vs nonischemic), assistance used and year of implantation
- Research of prognostic factors for postoperative and chronic right ventricular failure, prognostic factors of cardiovascular and all causes death.
Feasibility:
Based on historical data of the concerned centers (CHU Montpellier, Bordeaux and Toulouse) and recent predictions of french health authority HAS ("Haute Autorité de Santé"), 200 patients are provided in the observatory register, rhythm about 20-30 patients per year per center for a 3-year recruitment period Monitoring will be carried out by the referring physician for each patient at 1 and 6 months, and at 1 year in the usual care of pathology in each center with the possibility to adapt the follow-up date to +/- 1 month.
For patients who have moved and have therefore changed of referral center, an evaluation at one year will be made by mail or phone contact with the physician and / or patient.
Collect and circulation of patients' data:
Data will be collected under the patient's referring physician's responsibility in each center. Data will be entered directly into the electronic database (e-CRF) developed University of Montpellier.
Patient will be identified by the number of the center (1 = Bordeaux, 2 = Montpellier 3 = Toulouse) followed by the first letter of the name and the first initial and the center of the patient number in question (automatic chronological number according to the entry on the e-CRF - data coding is integrated into the e-CRF) Monitoring at 1 month, 6 months and 1 year, will be completed by the middle of referring physicians and entered directly into the electronic database.
There will be no traffic data on paper for these two steps.
In case of lost sight, follow-up at 1 year will be carried out by the centers, by phone or mail from the municipality of birth, the attending physician or cardiologist and patient, which requires knowledge of the date full birth patients to avoid confusion.
For the analysis, data will be anonymized (as shown above).
Members of the scientific committee, persons responsible for logistics and coordination statistics will have access to all of the identified data.
Research data is entered via an electronic case report forms (e-CRF) developed from the Capture System software (CLINSIGHT company), enabling quality control of data in real time. To meet regulatory requirements, this software complies with the FDA's recommendations on Computerized Systems for Managing Clinical Trials and electronic signature and standards (CDISC, ICH, GCP 2001/20 / EC ...). The connection is via a password and a unique identifier specific to each user that will give access only to his patients himself. An audit function is integrated allowing traceability of data as well as changes. The encrypted data will then be transmitted to the responsible center of the data-management via a secure internet connection.
The e-CRF must be composed of all the information required by the protocol.
Information and Consent of participants:
Prior to the completion of this research, the free, writing and informed consent of patients must be collected after information by the investigator during a consultation, and after a sufficient period of reflection.
Participants information for research should be written simply, in language understandable by the patient. After having read the participant and the investigator will have dated and signed the consent form (original archived by the investigator and an original will be given to research participants).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who underwent surgical LVAD implantation in one of the 3 participating centers (University Hospital of Montpellier, Toulouse and Bordeaux, France) for a period of 3 years, will be consecutively included whatever type of LVAD (Heartmate 2 or 3®, Jarvik®, Heartware®,…). Patients will be follow-up at 1 and 6 months, and 1 year. Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. Study of phenotypic characteristics will not change therapeutic approach of the medical teams.
Key inclusion criteria (4 listed)
- All patients undergoing implantation of LVAD support whatever make and type on one of the 3 participating centers (University Hospital of Montpellier, Toulouse and Bordeaux) during the period
- Free, informed and signed consent
- Adults
- Men or women Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. Study of phenotypic characteristics will not change the therapeutic approach of the medical teams.
Key exclusion criteria (3 listed)
- Patient unable to understand the nature and goals of the study and / or communication difficulties with the investigator
- Major protected by law (guardianship, curatorship or under judicial protection)
- Patient deprived of liberty by judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality rate
Time frame: 1 year
Mortality rate after one year for patients included in the research
6 secondary outcomes
Cardiovascular death rates
Time frame: 30 days
Cardiovascular death rates
Time frame: 6 months
Cardiovascular death rates
Time frame: 1 year
Mortality rate
Time frame: 30 days
Mortality rate
Time frame: 6 months
vital function
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2022.
- Individual participant dataSharing planned: Undecided. ND
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francois Roubille, MD PHD principal investigator
University Hospital, Montpellier
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic or Acute Advanced Heart Failure, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality rate (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2022.